The level of deal making in the pharmaceutical industry was negatively affected by the lack of venture funding invoked by the global economic downturn of 2008/2009. Fewer deals were concluded in 2009 as pharmaceutical companies forced to restructure and reduce their headcounts were reticent to part with their cash except for the most promising and innovative products and technologies. Even when they did sign deals, they were not willing to take on much risk.